Endocrine-Related Cancer

Papers
(The TQCC of Endocrine-Related Cancer is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)73
COVID-19 and androgen-targeted therapy for prostate cancer patients58
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms56
The epigenetic and transcriptional landscape of neuroendocrine prostate cancer49
Redifferentiation of radioiodine-refractory thyroid cancers49
Thyroid dysfunction and cancer incidence: a systematic review and meta-analysis47
Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms46
Androgen hazards with COVID-1945
Neuroendocrine neoplasm update: toward universal nomenclature41
Innovative imaging of insulinoma: the end of sampling? A review41
Molecular profiling for acromegaly treatment: a validation study33
The tumor microenvironment and immune responses in prostate cancer patients32
Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature32
Squamous cell carcinoma of thyroid: a unique type of cancer in World Health Organization Classification31
Therapy considerations in neuroendocrine prostate cancer: what next?30
Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?29
The role of vitamin D in breast cancer risk and progression29
HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas28
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop28
Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response27
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading27
Obese adipose tissue extracellular vesicles raise breast cancer cell malignancy27
Redifferentiation-facilitated radioiodine therapy in thyroid cancer27
Thyroid cancer in the age of COVID-1927
The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs)26
Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns26
The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer23
Molecular alterations in Hürthle cell nodules and preoperative cancer risk22
Mebendazole inhibits tumor growth and prevents lung metastasis in models of advanced thyroid cancer22
Heterogeneity of genomic profile in patients with HER2-positive breast cancer22
The complex regulation of NIS expression and activity in thyroid and extrathyroidal tissues22
GABPA-dependent down-regulation of DICER1 in follicular thyroid tumours21
Extrapulmonary poorly differentiated NECs, including molecular and immune aspects21
Genetic profile of advanced thyroid cancers in relation to distant metastasis21
The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches21
FOXO1 as a tumor suppressor inactivated via AR/ERβ signals in urothelial cells21
The impact of COVID-19 on and recommendations for breast cancer care: the Singapore experience20
New therapeutic opportunities for women with low-grade serous ovarian cancer20
50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?20
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: New and future perspectives for parathyroid carcinoma20
Genotype of CDC73 germline mutation determines risk of parathyroid cancer19
The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment19
Epigenetic and metabolic reprogramming of SDH-deficient paragangliomas19
Management changes for patients with endocrine-related cancers in the COVID-19 pandemic18
Antiangiogenic therapies for pheochromocytoma and paraganglioma18
Genomic classification of benign adrenocortical lesions17
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review17
Role of circadian rhythm disorders on EMT and tumour–immune interactions in endocrine-related cancers17
p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer17
Fibroblast growth factors signaling in bone metastasis16
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer16
Novel insights in cell cycle dysregulation during prostate cancer progression16
Phosphodiesterase 2A and 3B variants are associated with primary aldosteronism16
Risk factors for intraoperative complications in pheochromocytomas16
SREBP1 promotes invasive phenotypes by upregulating CYR61/CTGF via the Hippo-YAP pathway16
Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer16
Targeting EML4-ALK gene fusion variant 3 in thyroid cancer15
Tailoring the approach to radioactive iodine treatment in thyroid cancer15
B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors15
Neuroendocrine neoplasms of lung, pancreas and gut: a morphology-based comparison15
Cullin 3 targets the tumor suppressor gene ARMC5 for ubiquitination and degradation14
KLF5 and NFYA factors as novel regulators of prostate cancer cell metabolism14
LDLR-mediated lipidome–transcriptome reprogramming in cisplatin insensitivity14
Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC14
Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets14
Advanced RAI-refractory thyroid cancer: an update on treatment perspectives14
Chloroquine induces apoptosis in pancreatic neuroendocrine neoplasms via endoplasmic reticulum stress14
A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/− rats14
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC14
Gene expression profile in metastatic and non-metastatic parathyroid carcinoma14
Androgen receptor mutations for precision medicine in prostate cancer14
Metabolic and hormonal remodeling of colorectal cancer cell signaling by diabetes14
The immune tumour microenvironment of neuroendocrine tumours and its implications for immune checkpoint inhibitors13
Mass spectrometry-based steroid profiling in primary bilateral macronodular adrenocortical hyperplasia13
Fishing for neuroendocrine tumors13
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET13
Critical appraisal of MGMT in digestive NET treated with alkylating agents13
Molecular connections between circadian rhythm and genome maintenance pathways13
Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging13
Genome-wide crosstalk between steroid receptors in breast and prostate cancers13
Changing biological behaviour of NETs during the evolution of the disease: progress on progression12
The thyroid risk score (TRS) for nodules with indeterminate cytology12
Exercise intensity and markers of inflammation during and after (neo-) adjuvant cancer treatment12
CRISP3 expression drives prostate cancer invasion and progression12
TNM 8th edition in thyroid cancer staging: is there an improvement in predicting recurrence?12
Targeted genomic analysis of 364 adrenocortical carcinomas12
Adiponectin receptor activation inhibits prostate cancer xenograft growth12
Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview11
USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs11
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine11
Translating the immune microenvironment of thyroid cancer into clinical practice11
Regulation of docetaxel chemosensitivity by NR2F6 in breast cancer11
Follow-up of patients with thyroid cancer and antithyroglobulin antibodies: a review for clinicians11
IGF2 drives formation of ileal neuroendocrine tumors in patients and mice11
Metastatic medullary thyroid carcinoma: a new way forward11
The prognostic value of androgen receptor (AR) in HER2-enriched metastatic breast cancer11
The role of extracellular vesicles in prostate cancer with clinical applications11
Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures11
FOXE1 regulates migration and invasion in thyroid cancer cells and targets ZEB111
Pan-genomic characterization of high-risk pediatric papillary thyroid carcinoma11
Neutrophil elastase from myeloid cells promotes TSC2-null tumor growth11
Improved pasireotide response in USP8 mutant corticotroph tumours in vitro10
The role of membrane mucin MUC4 in breast cancer metastasis10
Photodynamic therapy enables tumor-specific ablation in preclinical models of thyroid cancer10
Treatment outcomes of advanced digestive well-differentiated grade 3 NETs10
Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers10
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The roles of AIP and GPR101 in familial isolated pituitary adenomas (FIPA)10
Leptin-elicited PBX3 confers letrozole resistance in breast cancer10
HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: GPR101, an orphan GPCR with roles in growth and pituitary tumorigenesis10
0.031775951385498